JETO Home • Issue Contents

Diindolylmethane and Lupeol therapy halt tumor development on experimental urothelial carcinogenesis
Bhoopathy Prabhu, Annamalai Sivakumar, Ramasamy Padma, Elayaperumal Manikandan, Jagathrakshakan Sri Nisha and Sivapatham Sundaresan

Urinary bladder cancer would be a serious health issue among human individuals. Current treatments are not effective so there is to be an optional therapy should be introduced to halt the reoccurrence of cancer. Phytochemicals does not own any adverse effect in patients with cancer. Our research is to investigate that the Diindolylmethane (DIM) and Lupeol treatment eliminates urinary bladder cancer development by activating the apoptosis by its anti-inflammatory properties. The male albino wistar rats were equally separated into 6 groups. Each group possesses 10 rats. G-I: Control. G-II: N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) was administered orally for 8 weeks. After 8 weeks of BBN toxicity, Dimethylarsinic acid (DMA) was provided for 28 weeks in drinking water. G-III and G-IV: After BBN initiation, DMA was provided for 28 weeks in drinking water. Diindolylmethane and Lupeol were also administered orally for 28 weeks along with DMA. G-V and G-VI: Diindolylmethane alone and Lupeol alone were administered orally for 36 weeks. The experimental rats were euthanized at 36th week. The urinary bladder was macroscopically and microscopically analyzed in control and treated groups. Diindolylmethane and Lupeol therapy inhibited the tumor formation in the urinary bladder. Our study proved that both Diindolylmethane and Lupeol are being capable of targeting these signaling pathways which would make them potentially applicable to cancer chemoprevention and treatment.

Keywords: Urinary Bladder Cancer; N-butyl-N-(4-hydroxybutyl)

Full Text (IP)